Can-Fite secures Eurasian patent allowance for Piclidenoson in Lowe syndrome
CANF•Can-Fite BioPharma received a Eurasian patent allowance covering Piclidenoson for Lowe syndrome and Dent disease 2, subject to formalities. A planned six-month Phase 2 trial will evaluate twice-daily oral treatment in five adults with Lowe syndrome.
1. Patent and trial plans
Can-Fite BioPharma received a Eurasian patent allowance covering Piclidenoson for Lowe syndrome and Dent disease 2; the grant remains subject to formalities. An agreement with patent owner Fondazione Telethon provides development, commercialization and out-licensing rights for the indications. A planned open-label, single-center Phase 2 trial will evaluate twice-daily oral Piclidenoson for six months in five adults with genetically confirmed Lowe syndrome, with renal uptake of 99mTc-DMSA as its primary endpoint.
